

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings of claims in the application:

LISTING OF CLAIMS:

1-53. (cancelled)

54. (previously presented) A method of treating SARS (Severe Acute Respiratory Syndrome) treatment, comprising administering an effective amount of INDO and its pharmaceutically acceptable salts and derivatives to a subject in need of said treatment thereof.

55. (previously presented) A method of treating hemorrhagic fevers, comprising administering an effective amount of INDO and its pharmaceutically acceptable salts and derivatives to a subject in need of said treatment thereof.

56. (previously presented) The method according to claim 55 wherein fever is caused by Filovirus, Bunyavirus, Arenavirus or Flavivirus.

57. (previously presented) A method of treating viral diseases caused by viruses selected from the group consisting of: Parainfluenza viruses, A, B and C influenza viruses; Respiratory Syncytial Virus; Reovirus; Rotavirus; Coronavirus; Parvovirus; Adenovirus; Papovavirus; Papillomavirus; Poxvirus; and Filovirus, comprising administering an effective amount of INDO and its pharmaceutically acceptable salts and derivatives to a subject in need of said treatment thereof.

58. (previously presented) The method according to claim 54 wherein INDO salts and derivatives comprise alkali metal salts, alkaline earth metal salts, aluminium salts, zinc salts, ammonium salts, inorganic acid addition salts, and/or organic acid addition salts.

59. (previously presented) The method according to claim 54 wherein said INDO is in the form of a veterinary medicine, agriculture product, or aquaculture product.

60. (previously presented) The method according to claim 54 wherein INDO is administered at concentrations ranging between 10 and 1000 microM.

61. (previously presented) Use according to claim 54, wherein INDO is administered at concentrations ranging between 100 and 400 microM.

62. (previously presented) The method according to claim 54 wherein INDO is administered in combination with pharmaceutically acceptable carriers comprising: preserving agents, solubilising agents, stabilising agents, wetting agents, emulsifiers, sweeteners, colourants, odourants, salts, buffers, coating agents and or antioxidants.

63. (previously presented) The method according to claim 54 wherein INDO is administered by the oral, rectal, nasal, topical, vaginal, parenteral routes.

64. (previously presented) The method according to claim 54 wherein INDO is administered in combination with a carrier that is able to penetrate BBB.

65. (currently amended) A pharmaceutical ~~composition~~
composition comprising INDO and/or salts and/or derivatives
thereof in combination with pharmaceutically effective amounts of
at least one compound comprising: Interferon, metals and
corresponding salts—~~and~~ and/or derivatives, prostanoids,
antiviral drugs;—~~and~~ and/or corresponding mixtures for the
treatment of diseases comprising: tissue cytoprotection, SARS,
gastroenteritis, hemorrhagic fevers, respiratory diseases,
diseases caused by Coronavirus, Parainfluenza viruses, Influenza
viruses, Respiratory Syncytial Virus, virus-caused neoplasias,
viral encephalitis, viral diseases in general, and viral diseases
caused by genetically modified viruses.

66. (currently amended) The composition according to
claim 65, wherein INDO salts—~~and~~ and/or derivatives comprise
alkali metal salts, alkaline earth metal salts, aluminium salts,
zinc salts, ammonium salts, inorganic acid addition salts, and/or
organic acid addition salts.

67. (previously presented) The composition according
to claim 65, wherein prostanoids comprise: cyclopentenone
prostanoids, PGA_1 , PGA_2 , PGJ_1 , PGJ_2 , $\text{delta}^{12}\text{-PGJ}_2$, and/or 15-deoxy-
 $\text{delta}^{12,14}\text{-PGJ}_2$.

68. (currently amended) The composition according to
claim 65, wherein the metals comprise: zinc, gold, selenium,
bismuth ~~and~~ and/or cadmium, or corresponding salts—~~and~~ and/or
derivatives.

69. (currently amended) The composition according to
claim 65, wherein the metal salts—~~and~~ and/or derivatives

comprise: chloride, sulfate, lactate, citrate, iodate, maleate, thiomaleate, diethyl-dithiocarbamate, butyl salicylate, fumarate, succinate, and/or porfirin tetrakis metachloride.

70. (currently amended) The composition according to claim 65, wherein the metal is Zn and and/or corresponding salts ~~and~~ and/or derivatives comprise: ZnCl_2 , Zn sulfate, Zn lactate, Zn iodate, Zn diethyl-dithiocarbamate, Zn butyl salicylate, and/or Zn porfirin tetrakis metachloride.

71. (previously presented) The composition according to claim 65, wherein said antiviral drugs comprise: Ribavirin, acyclovir, amantadine, rimantadine, influenza virus neuroaminidase inhibitors, idoxuridine, fosfonacetic acid, AZT, DDC, and/or viral protease inhibitors.

72. (previously presented) The composition according to claim 71, wherein the viral protease inhibitors are HIV protease inhibitors.

73. (currently amended) The composition according to claim 65, wherein INDO is administered in combination with pharmaceutically acceptable carriers comprising: preserving agents, solubilising agents, stabilising agents, wetting agents, emulsifiers, sweeteners, colourants, odourants, salts, buffers, coating agents, and/or antioxidants.

74. (currently amended) The composition according to claim 65, wherein INDO is in an oral, rectal, nasal, topical, vaginal, or parenteral form.

75. **(currently amended)** The composition according to claim 65, wherein INDO in combination with a carrier that is able to penetrate BBB.

76. **(previously presented)** The composition according to claim 65, further comprising a pharmaceutically acceptable vector.

77. **(new)** A pharmaceutical composition comprising INDO in combination with a pharmaceutically effective amount of at least one metal and/or corresponding salts and/or derivatives.

78. **(new)** The composition according to claim 65, wherein the metals comprise: gold, selenium, or bismuth, and/or corresponding salts and/or derivatives.